$HGEN 2 @MayoClinic heavyweights will be talking with Dr. Birx on Monoclonal antibodies. @MayoProceedings@MayoClinic is basically spearheading the phase 3 Lenzilumab trials... this could be a diamond in the rough that could put lenz on the national media very soon... pic.twitter.com/qRLmPiGB41